Sinovac Initiates Influenza A(H1N1) Vaccine Production

Sinovac has announced that it has initiated the production of a vaccine against influenza A (H1N1) virus. The virus seed was received from US CDC, and was delivered to the company on June 8, 2009.

In order to supply enough vaccines to protect the public within a reasonable period of time, Sinovac and other flu manufactures in China have collaborated to co-manufacture Panflu. Sinovac’s pandemic influenza vaccine with H1N1 virus seed has got approval from China’s State Food and Drug Administration (SFDA).

SFDA has cleared the pandemic influenza vaccine for fast track approval, while the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) has committed a simultaneous lot release for H1N1 vaccine to ensure supply by early October 2009.

Mr. Weidong Yin, Chairman, President and CEO, Sinovac, said: ”In the midst of a global outbreak and transmission of H1N1, our mission as a vaccine developer and manufacturer is to protect the public. We are very pleased to offer our expertise in supplying preventative vaccines to the national and local authorities as they focus on controlling the transmission of the H1N1 virus”.

“Today, Sinovac has received the virus seed, we will start the production of H1N1 vaccine immediately from production of virus seed lots. Throughout this critical time, Sinovac will continue its commitment to providing safe and high quality vaccines,” he added.